Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases

Soluble Vascular Endothelial Growth Factor Decoy Receptor FP3 Exerts Potent Antiangiogenic Effects

(2012) De-Chao Yu et al.   MOLECULAR THERAPY

FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo

(2011) Ketao Jin et al.   Clinical & Translational Oncology

Establishment of a PDTT Xenograft Model of Gastric Carcinoma and its Application in Personalized Therapeutic Regimen Selection

(2011) Ketao Jin et al.   HEPATO-GASTROENTEROLOGY

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

(2011) Ketao Jin et al.   PLoS One

Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review

(2010) Ketao Jin et al.   Clinical & Translational Oncology

Advances in Combination of Antiangiogenic Agents Targeting VEGF-binding and Conventional Chemotherapy and Radiation for Cancer Treatment

(2010) Li-Song Teng et al.   Journal of the Chinese Medical Association

A Phase 1 Study of KH902, a Vascular Endothelial Growth Factor Receptor Decoy, for Exudative Age-Related Macular Degeneration

(2010) Ming Zhang et al.   OPHTHALMOLOGY

Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further?

(2010) Ketao Jin et al.   Personalized Medicine

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

The Pharmacology Study of a New Recombinant Human VEGF Receptor-Fc Fusion Protein on Experimental Choroidal Neovascularization

(2008) Ming Zhang et al.   PHARMACEUTICAL RESEARCH